Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Advances in single-cell RNA sequencing and its applications in cancer research. | J Hematol Oncol | 2023 | 37612741 | PubTator, text mining | PubMed |
| Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer. | J Immunother Cancer | 2023 | 37607770 | PubTator, text mining | PubMed |
| Multi-omics analyses based on genes associated with oxidative stress and phospholipid metabolism revealed the intrinsic molecular characteristics of pancreatic cancer. | Sci Rep | 2023 | 37604837 | PubTator, text mining | PubMed |
| Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma. | Neoplasia | 2023 | 37603953 | PubTator, text mining | PubMed |
| Therapeutic targeting of leukemia stem cells in acute myeloid leukemia. | Front Oncol | 2023 | 37601659 | PubTator, text mining | PubMed |
| Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. | Arch Toxicol | 2023 | 37597078 | PubTator, text mining | PubMed |
| Comprehensive characterization of pyroptosis phenotypes with distinct tumor immune profiles in gastric cancer to aid immunotherapy. | Aging (Albany NY) | 2023 | 37595258 | PubTator, text mining | PubMed |
| A new marker constructed from immune-related lncRNA pairs can be used to predict clinical treatment effects and prognosis: in-depth exploration of underlying mechanisms in HNSCC. | World J Surg Oncol | 2023 | 37592311 | PubTator, text mining | PubMed |
| Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. | Mol Ther Oncolytics | 2023 | 37583386 | PubTator, text mining | PubMed |
| The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. | Exp Hematol Oncol | 2023 | 37580826 | PubTator, text mining | PubMed |
| Diagnostic and Prognostic Value of Protein Post-translational Modifications in Hepatocellular Carcinoma. | J Clin Transl Hepatol | 2023 | 37577238 | PubTator, text mining | PubMed |
| FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab. | Front Immunol | 2023 | 37575254 | PubTator, text mining | PubMed |
| Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. | Int J Mol Sci | 2023 | 37569598 | PubTator, text mining | PubMed |
| Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy. | Int J Mol Sci | 2023 | 37569548 | PubTator, text mining | PubMed |
| XCR1 expression distinguishes human conventional dendritic cell type 1 with full effector functions from their immediate precursors. | Proc Natl Acad Sci U S A | 2023 | 37566635 | PubTator, text mining | PubMed |
| Dynamic thresholding and tissue dissociation optimization for CITE-seq identifies differential surface protein abundance in metastatic melanoma. | Commun Biol | 2023 | 37563418 | PubTator, text mining | PubMed |
| Development and validation of a N6 methylation regulator-related gene signature for prognostic and immune response prediction in non-small cell lung cancer. | Am J Cancer Res | 2023 | 37560004 | PubTator, text mining | PubMed |
Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop. | Virchows Arch | 2023 | 37555980 | PubTator, text mining | PubMed |
| Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes. | Discov Oncol | 2023 | 37555866 | PubTator, text mining | PubMed |
| Radionecrosis mimicking pseudo‑progression in a patient with lung cancer and brain metastasis following the combination of anti‑PD‑1 therapy and stereotactic radiosurgery: A case report. | Oncol Lett | 2023 | 37545620 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=29